Beam Therapeutics (NASDAQ: BEAM)
Beam Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Beam Therapeutics Company Info
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
News & Analysis
Why Beam Therapeutics Stock Zoomed 17% Higher Today
JPMorgan Chase becomes the latest institution in the company's bull pen.
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
Analysts have high hopes for these three innovation companies in 2024.
Is Beam Therapeutics Stock a Buy Now?
It has plenty of money, but it'll be facing plenty of competition, too.
Top ETFs Tracking CRISPR Gene Editing
These exchange-traded funds track companies in this biotech space.
Investing in Top CRISPR Companies
These CRISPR stocks could be big winners for patient investors.
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology.
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?
Some of the strategic shifts proposed by management are for the better.
5 Reasons Beam Therapeutics Remains a Risky Stock
Shares of the gene-editing biotech might not have hit rock bottom yet.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.